Patient Perspectives on Switching from Infliximab to Infliximab‐dyyb in Patients with Rheumatologic Diseases in the United States.
- Published in:
- ACR Open Rheumatology, 2019, v. 1, n. 1, p. 52, doi. 10.1002/acr2.1007
- By:
- Publication type:
- Article
Works by Bhardwaja, Bharati
Results: 5
1
2
Technology-Enabled Outreach to Patients Taking High-Risk Medications Reduces a Quality Gap in Completion of Clinical Laboratory Testing.
- Published in:
- Population Health Management, 2020, v. 23, n. 1, p. 3, doi. 10.1089/pop.2019.0033
- By:
- Publication type:
- Article
3
Impact of Prescription Benefit Coverage Limits on Sevelamer Hydrochloride Adherence for Patients with ESRD.
- Published in:
- American Health & Drug Benefits, 2009, v. 2, n. 6, p. 242
- By:
- Publication type:
- Article
4
Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System.
- Published in:
- BioDrugs, 2022, v. 36, n. 1, p. 1, doi. 10.1007/s40259-021-00510-w
- By:
- Publication type:
- Article
5
Improving Prescribing Safety in Patients with Renal Insufficiency in the Ambulatory Setting: The Drug Renal Alert Pharmacy (DRAP) Program.
- Published in:
- Pharmacotherapy, 2011, v. 31, n. 4, p. 346, doi. 10.1592/phco.31.4.346
- By:
- Publication type:
- Article